

Helix BioMedix to Present at the Wall Street Analyst Forum Conference

Sep 17, 2007 - Bothell, Washington

Helix BioMedix, Inc., (OTCBB:HXBM - News), a biopharmaceutical company with an extensive library of diverse bioactive peptides, today announced that R. Stephen Beatty, President and Chief Executive Officer, will present at the Wall Street Analyst Forum Conference at the Princeton Club in New York, New York. Mr. Beatty is scheduled to present on Thursday, September 20 at 4:00 in the afternoon.

A live Web cast of Helix BioMedix's presentation may be accessed at the Company's corporate Web site (Investor Relations Link), at www.helixbiomedix.com at 4:00 p.m. EDT on September 20, 2007. Access to the replay will be available two hours after the Web cast and continuing for approximately 30 days.

About Helix BioMedix, Inc.

Helix BioMedix, Inc. is a biopharmaceutical company with an extensive library of diverse bioactive peptides and patents covering six distinct classes and hundreds of thousands of peptide sequences. Our mission is to enrich clinical practice and the patient/consumer experience by developing topically applied products, which offer the health, beauty and safety benefits of advanced bioactive small molecule technology. Our vision is to be recognized as the world leader in the identification, qualification and commercialization of natural and synthetic peptide technology..

Our core competencies include peptide design, synthesis and characterization together with assay development, screening, tissue culture and microbiology, leveraged through relationships with contract research organizations and peptide manufacturers. We have the capability to take our product development programs from theoretical concept to a validated and qualified skin care active ingredient fully validated as to efficacy and safety. Applications for Helix BioMedix peptides include anti-aging cosmeceutical skin care and acne treatment as well as other topical anti-infective pharmaceuticals and wound healing applications. In addition, we are developing finished, peptide-based products to market with our partners.

More information about the company and its proprietary peptides may be found on the company's website at www.helixbiomedix.com.

Contacts:

Helix BioMedix Contact:

R. Stephen Beatty
President and CEO
425-402-8400
sbeatty@helixbiomedix.com

or

Investor Contact:

Shelton Group Investor Relations
Ryan Bright

972-239-5119 X 159

rbright@sheltongroup.com

Source: Helix BioMedix, Inc.